-
- THE SPOTLIGHT
-
- Warfare Chemicals being Tested: The strange-looking streaks
in the sky aren't your imagination.
-
- They are anti-bacteriological warfare chemicals being
tested by the federal government. And the public has been kept in the dark.
-
- The chemical spraying to the "unconventional pathogen
countermeasures program" of the top secret Defense Advanced Research
Projects Agency (DARPA).
-
- NOTE : Novavax is a bio pharmaceuticals company. BCTP
is made of water, soybean oil, Triton X 100 detergent and the solvent tri-n-butyl
phosphate. BCTP envelops the VIRUSES and SPORES, causing them to explode
and thus destroying them upon contact.
-
- http://www.spotlight.org/01_07_00/Chemicals/chemicals.html
-
- ********* Novavax, Inc. : http://www.novavax.com/
-
- NOTE : BCTP's research studies were funded by the Defense
Advanced Research Projects Agency (DARPA).
-
- BCTP appears to inactivate the virus on contact."
-
- The research is funded by DARPA's "Unconventional
Pathogen Countermeasures Program"
-
- [GO TO : http://www.darpa.mil/DSO/rd/UPC/index.html
]. The U-M and Novavax have filed a patent application covering BCTP's
use as a decontamination agent for various anti-microbial applications.
-
- *** There IS an "Alien" INVADER Biological
THREAT! Research and Development Areas : http://www.darpa.mil/DSO/rd/Abmt/Pathogen.html
-
- Advanced Biological and Medical Technologies:
Biological Warfare Defense Unconventional Pathogen Countermeasures
-
- The goal of the Unconventional Pathogen Countermeasures
program is to develop and demonstrate defensive technologies that afford
the greatest protection to uniformed warfighters, and the defense personnel
who support them, during U.S. military operations. While no defense may
stop a determined adversary from unleashing biological weapon, a sufficiently
robust array of pathogen defenses and countermeasures ,Äî deterrents
in their own right ,Äî will reduce the probable damage that
would result from biological weapons used in a particular operation.
-
- The most sinister offensive biological warfare scenario
employs surprise, immediate proximity, and rapidly lethal, persistent agents
in overwhelming quantities. Under these circumstances, real-time sensing,
donning of physical protection, and conventional nonmedical countermeasures
are only marginally effective. An effective operational defense ideally
requires instantly available or emplaced countermeasures that can defeat
biological threats as they enter the body and before they reach and attack
target cells and tissues.
-
- The focus of the Unconventional Pathogen Countermeasures
program is the development of revolutionary, broad-spectrum, medical countermeasures
against significantly pathogenic microorganisms and/or their pathogenic
products. These countermeasures will be versatile enough to eliminate biological
threats, whether from natural sources or modified through bioengineering
or other manipulation. They will also have the potential to provide protection
both within the body and at the most common portals of entry (e.g., inhalation,
ingestion, transcutaneous). Strategies include but are not limited to:
-
- Defeat of a pathogen's ability to enter the body, traverse
the bloodstream or lymphatics, and enter target tissues.
-
- Identification of novel pathogen vulnerabilities based
on fundamental, critical molecular mechanisms of survival or pathogenesis
(e.g., Type III secretion, cellular energetics, virulence modulation).
-
- Construction of unique, robust vehicles for the delivery
of countermeasures into or within the body.
-
- Modulation of the advantageous and/or deleterious aspects
of the immune response to significantly pathogenic microorganisms and/or
their pathogenic products in the body. *******************************
-
- CHEMTRAILS & THE BLACK DEATH
-
- Excerpted from: http://www.theforbiddenknowledge.com/chemtrails/index.htm
-
- A great many people throughout Europe and other Plague
stricken regions of the world were reporting that outbreaks of the Plague
were caused by foul-smelling "mists". Those mists frequently
appeared after unusually bright lights in the sky. The historian quickly
discovers that "mists" were reported far more frequently and
in many more locations than were rodent infestations. The Plague years
were, in fact, a period of heavy UFO activity.
-
- *********
-
- LUCAS : Flu comes from Outer Space, claim scientists
-
- Excerpted from : http://members.aol.com/rubie2zday/index.html#flu
In a report to be published in the journal Current Science, they claim
the outbreak was caused by dust deposited high in the atmosphere by passing
comets being forced down to earth by energy generated by cooler patches
on the sun's surface, known as sunspots. * In a report to be published
in the journal Current Science, they claim the outbreak was caused by DUST
deposited high in the atmosphere by passing comets being forced down to
earth by energy generated by cooler patches on the sun's surface, known
as sunspots.
-
- They reach the peak of their activity, the maxima, every
11 years... The latest cycle began to peak in September and the maxima
is due sometime this year.
-
-
- -- Bill Hamilton Executive Director Skywatch International,
Inc. Website: home.earthlink.net/~skywatcher22
-
- _________
-
- And furthermore:
-
-
- Maxygen Announces $6.7 Million Grant
from DARPA to Develop Aerosolized Vaccines
-
- link
- 1-22-2000
-
-
- Redwood City, CA, September 28, 1999. Maxygen announced
today that it has received a $6.7 million three-year grant from the Defense
Advanced Research Agency (DARPA) to use its proprietary MolecularBreeding
directed evolution technology (also known as "DNA Shuffling")
to develop aerosol-based vaccines to protect against a broad spectrum of
pathogens.
-
- Aerosol delivery of prophylactic and therapeutic agents
is potentially the simplest and most cost-effective way to protect or treat
humans and animals from disease epidemics. In addition to this recent DARPA
grant, Maxygen is the recipient of two additional DARPA grants in the vaccine
area. In February 1998, Maxygen received a $5.6 million grant to evolve
novel DNA vectors for efficient delivery and expression of pathogen antigens,
and in April 1999, the Company received a grant of $7.7 million to generate
novel vaccine antigens for a wide range of pathogens.
-
- Maxygen, Inc., headquartered in Redwood City, CA is a
private biotechnology company that is focused on the development of novel
and improved commercial products using its proprietary MolecularBreeding
directed evolution technology for a variety of industries including human
therapeutics, chemicals, vaccines, industrial enzymes, and agriculture.
The Company is the leader in nucleic acid recombination technologies for
imparting new properties into single genes, multi-gene systems, pathways,
vectors and genomes. Maxygen has commercial relationships with several
companies including Novo Nordisk in certain areas of industrial enzymes,
Pioneer Hi-Bred and ZenecaAgrochemicals for specific products in agriculture
and DSM Anti-Infectives for improved manufacturing of certain classes of
penicillin antibiotics. Maxygen was founded in a March 1997 spinout from
Glaxo Wellcome-Affymax, led by biotech entrepreneur Alejandro Zaffaroni,
and MolecularBreeding inventor Pim Stemmer.
-
-
- NovaVax Denies Role In Chemtrials 1-28-00
-
- (NovaVax was asked about the chemtrail issue. Here is
the company's response...)
-
- In response to your question regarding our testing an
agent on the American Public. Rest assured that we ARE NOT testing ANY
agent on the American Public.
-
- We are in the business of researching and developing
drug delivery platforms (specifically transdermal in the form of a hand
cream) not drugs or chemical agents. Our product is currently being tested
in a controlled clinical study. The drug being used in our platform is
Estradiol. We are also collaborating on many types of vaccines, such as
influenza and human HPV.
-
- I hope this will alleviate your concerns about our company.
If you have any further questions please contact us again.
-
- If at all possible I would appreciate your providing
us with the source of your information.
-
-
- Jessica F. Gandy Controller/Human Resources jgandy@novavax.com
|
